Also trades as: 2552.HK (HKSE) · $vol 1M
HUMDF OTC
Hua Medicine (Shanghai) Ltd.
1W: +0.0%
1M: -13.7%
3M: -13.7%
YTD: -28.5%
1Y: -28.5%
3Y: -34.8%
$0.29
+0.00 (+0.00%)
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Income Trends
Revenue
$480M
+87.7% ▲
5Y CAGR: +123.2%
Gross Profit
$273M
+119.0% ▲
5Y CAGR: +99.4%
Operating Income
-$141M
+60.0% ▲
Net Income
$1.1B
+530.9% ▲
EPS (Diluted)
$1.05
+520.0% ▲
EBITDA
-$110M
+47.1% ▲
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $0 | $18M | $77M | $256M | $480M |
| YoY Growth | -100.0% | +0.0% | +335.3% | +234.0% | +87.7% |
| Cost of Revenue | $0 | $10M | $39M | $131M | $207M |
| Gross Profit | $0 | $8M | $37M | $125M | $273M |
| Gross Margin | — | 43.7% | 48.8% | 48.7% | 56.9% |
| R&D Expenses | $187M | $130M | $172M | $215M | $142M |
| SG&A Expenses | $135M | $145M | $204M | $270M | $273M |
| Operating Expenses | $322M | $275M | $326M | $477M | $414M |
| Operating Income | -$321M | -$267M | -$289M | -$353M | -$141M |
| Operating Margin | — | -1517.8% | -377.4% | -137.8% | -29.4% |
| Interest Expense | $4M | $4M | $8M | $9M | $8M |
| Income Before Tax | -$326M | -$204M | -$211M | -$250M | $1.1B |
| Tax Expense | $0 | $0 | $0 | $0 | $0 |
| Net Income | -$331M | -$204M | -$211M | -$250M | $1.1B |
| Net Margin | — | -1157.8% | -275.7% | -97.8% | 224.4% |
| EPS (Diluted) | $-0.34 | $-0.21 | $-0.22 | $-0.25 | $1.05 |
| EBITDA | -$310M | -$168M | -$167M | -$207M | -$110M |
| Shares Outstanding | 957M | 967M | 977M | 981M | 1.00B |